ABSTRACT
Current therapeutic approaches for the treatment of asthma have limitations in their ability to target all the features of the disease. Indeed, existing pharmacological asthma therapies are based on decades old strategies that were developed prior to the rapid growth in knowledge stemming from cell and molecular biology in the past decade. Thus, there is an unmet need for developing new drugs to target these features along with improved efficacy and safety. In the present review, the limitations of prevalent pharmacological asthma therapy are discussed briefly, and some explanations are suggested as to why new therapeutic targets are required to treat asthma, and finally directions for novel asthma therapies are proposed.
Subject(s)
Animals , Asthma/drug therapy , Asthma/enzymology , Asthma/genetics , Asthma/metabolism , Bronchodilator Agents/metabolism , Bronchodilator Agents/pharmacology , Bronchodilator Agents/therapeutic use , Cytokines/metabolism , Enzyme Inhibitors/metabolism , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Humans , Oligonucleotides/metabolism , Oligonucleotides/therapeutic use , Transcription Factors/antagonists & inhibitorsABSTRACT
Los medicamentos para tratar el asma utilizan fundamentalmente la vía inhaladora. La utilidad de los espaciadores con válvulas (aerocámaras) está demostrada; sin embargo, recientemente se ha propuesto como alternativa más económica el uso de espaciadores sin válvula. La eficacia clínica de éstos no se ha demostrado hasta el momento.